OncoMatch/Clinical Trials/NCT07441993
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
Is NCT07441993 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Orelabrutinib for marginal zone lymphoma.
Treatment: Orelabrutinib — This is a single-arm, multicenter, prospective, phase II study. The primary objective is to assess the efficacy and safety of orelabrutinib in treatment-naïve patients with marginal zone lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage I, II
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
ANC ≥1.5×10^9/L, platelets ≥75×10^9/L, hemoglobin ≥75g/L; if bone marrow involvement: ANC ≥1.0×10^9/L, platelets ≥50×10^9/L, hemoglobin ≥50g/L
Kidney function
serum creatinine ≤1.5×ULN
Liver function
Total bilirubin ≤1.5×ULN, AST or ALT ≤2×ULN
Cardiac function
NYHA Class II or higher congestive heart failure, unstable angina, MI within 6 months, arrhythmia requiring treatment, LVEF <50%, primary cardiomyopathy, QTc >470 ms (female) or >450 ms (male), symptomatic coronary artery disease requiring medication, poorly controlled hypertension
Blood tests: ANC ≥1.5×10^9/L, platelets ≥75×10^9/L, hemoglobin ≥75g/L; if accompanied by bone marrow involvement, ANC ≥1.0×10^9/L, platelets ≥50×10^9/L, hemoglobin ≥50g/L; Blood biochemistry: Total bilirubin ≤1.5×ULN, AST or ALT ≤2×ULN; serum creatinine ≤1.5×ULN; NYHA Class II or higher congestive heart failure, unstable angina, MI within 6 months, arrhythmia requiring treatment, LVEF <50%, primary cardiomyopathy, QTc >470 ms (female) or >450 ms (male), symptomatic coronary artery disease requiring medication, poorly controlled hypertension
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07441993 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage I or II is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages